Melanie S. Vacchio

Melanie S. Vacchio

Auto-generated profile, based on publicly available information

Melanie S. Vacchio

Laboratory of Immune Cell Biology and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TCThomas Ciucci
Thomas Ciucci
MVMelanie S. Vacchio
Melanie S. Vacchio
TCTing Chen
Ting Chen
JNJia Nie
Jia Nie
LCLaura B. Chopp
Laura B. Chopp
RBRémy Bosselut
Rémy Bosselut
During the immune response, CD4+ T cells differentiate into distinct effector subtypes, including follicular helper T (Tfh) cells that help B cells, and into memory cells. Tfh and memory cells are required for long-term immunity; both depend on the transcription factor Bcl6, raising the question whether they differentiate through similar mechanisms. Here, using single-cell RNA and ATAC sequencing, we show that virus-responding CD4+ T cells lacking both Bcl6 and Blimp1 can differentiate into cells with transcriptomic, chromatin accessibility, and functional attributes of memory cells but not of Tfh cells. Thus, Bcl6 promotes memory cell differentiation primarily through its repression of Blimp1. These findings demonstrate that distinct mechanisms underpin the differentiation of memory and Tfh CD4+ cells and define the Bcl6–Blimp1 axis as a potential target for promoting long-term memory T cell differentiation.

10 June 2022 in Science Immunology
Verified
Journal Article
Closed access
YGYayi Gao
Yayi Gao
MZMonica Zamisch
Monica Zamisch
MVMelanie Vacchio
Melanie Vacchio
LCLaura Chopp
Laura Chopp
TCThomas Ciucci
Thomas Ciucci
RBRémy Bosselut
Rémy Bosselut
Although BTB–zinc finger (BTB-ZF) transcription factors control the differentiation of multiple hematopoietic and immune lineages, how they function is poorly understood. The BTB-ZF factor Thpok controls intrathymic CD4 + T cell development and the expression of most CD4 + and CD8 + lineage genes. Here, we identify the nucleosome remodeling and deacetylase (NuRD) complex as a critical Thpok cofactor. Using mass spectrometry and coimmunoprecipitation in primary T cells, we show that Thpok binds NuRD components independently of DNA association. We locate three amino acid residues within the Thpok BTB domain that are required for both NuRD binding and Thpok functions. Conversely, a chimeric protein merging the NuRD component Mta2 to a BTB-less version of Thpok supports CD4 + T cell development, indicating that NuRD recruitment recapitulates the functions of the Thpok BTB domain. We found that NuRD mediates Thpok repression of CD8 + lineage genes, including the transcription factor Runx3 , but is dispensable for Cd4 expression. We show that these functions cannot be performed by the BTB domain of the Thpok-related factor Bcl6, which fails to bind NuRD. Thus, cofactor binding critically contributes to the functional specificity of BTB-ZF factors, which control the differentiation of most hematopoietic subsets.

1 September 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ACAndrea C. Carpenter
Andrea C. Carpenter
EWElizabeth Wohlfert
Elizabeth Wohlfert
LCLaura B. Chopp
Laura B. Chopp
MVMelanie S. Vacchio
Melanie S. Vacchio
JNJia Nie
Jia Nie
RBRémy Bosselut
Rémy Bosselut
The CD4+ lineage–specific transcription factor Thpok is required for intrathymic CD4+ T cell differentiation and, together with its homolog LRF, supports CD4+ T cell helper effector responses. However, it is not known whether these factors are needed for the regulatory T cell (Treg) arm of MHC class II responses. In this study, by inactivating in mice the genes encoding both factors in differentiated Tregs, we show that Thpok and LRF are redundantly required to maintain the size and functions of the postthymic Treg pool. They support IL-2–mediated gene expression and the functions of the Treg-specific factor Foxp3. Accordingly, Treg-specific disruption of Thpok and Lrf causes a lethal inflammatory syndrome similar to that resulting from Treg deficiency. Unlike in conventional T cells, Thpok and LRF functions in Tregs are not mediated by their repression of the transcription factor Runx3. Additionally, we found that Thpok is needed for the differentiation of thymic Treg precursors, an observation in line with the fact that Foxp3+ Tregs are CD4+ cells. Thus, a common Thpok-LRF node supports both helper and regulatory arms of MHC class II responses.

24 November 2023 in Science Immunology
Verified
Journal Article
Closed access
LCLaura B. Chopp
Laura B. Chopp
XZXiaoliang Zhu
Xiaoliang Zhu
YGYayi Gao
Yayi Gao
JNJia Nie
Jia Nie
JSJatinder Singh
Jatinder Singh
RBRémy Bosselut
Rémy Bosselut
How CD4 + lineage gene expression is initiated in differentiating thymocytes remains poorly understood. Here, we show that the paralog transcription factors Zfp281 and Zfp148 control both this process and cytokine expression by T helper cell type 2 (T H 2) effector cells. Genetic, single-cell, and spatial transcriptomic analyses showed that these factors promote the intrathymic CD4 + T cell differentiation of class II major histocompatibility complex (MHC II)–restricted thymocytes, including expression of the CD4 + lineage–committing factor Thpok. In peripheral T cells, Zfp281 and Zfp148 promoted chromatin opening at and expression of T H 2 cytokine genes but not of the T H 2 lineage–determining transcription factor Gata3. We found that Zfp281 interacts with Gata3 and is recruited to Gata3 genomic binding sites at loci encoding Thpok and T H 2 cytokines. Thus, Zfp148 and Zfp281 collaborate with Gata3 to promote CD4 + T cell development and T H 2 cell responses.

18 June 2026 in Science
Verified
Journal Article
Closed access
QLQiaoshi Lian
Qiaoshi Lian
JNJia Nie
Jia Nie
JSJatinder Singh
Jatinder Singh
QCQiang Chen
Qiang Chen
JMJennifer Matta
Jennifer Matta
RBRémy Bosselut
Rémy Bosselut
Most cancer immunotherapy strategies are focused on direct tumor killing by immune cells, especially T lymphocytes. Clinical and conceptual limitations of these approaches create a need for additional strategies. We identified a tumor stroma–targeting mechanism in which tumor antigen–specific CD4 + T cells inhibit tumor growth through myeloid cell and tumor necrosis factor (TNF)–dependent vascular damage. Multiplex immunofluorescence and single-cell and tissue transcriptomics showed that CD4 + T cells trigger the formation of perivascular myeloid cell clusters containing “classically activated” macrophages that produce TNF in response to T cell–derived interleukin-3. TNF causes intratumoral endothelial damage and blood supply disruption, which are associated with localized tumor cell death. Thus, intratumoral antigen-triggered T cell activation can mediate antitumor effects without direct recognition of living tumor cells, thereby avoiding many of the inhibitory mechanisms that limit anti-tumor immunity.

1 April 2001 in Gastroenterology
Verified
Journal Article
Closed access
DFDenis Franchimont
Denis Franchimont
JGJerome Galon
Jerome Galon
MVMelanie Vacchio
Melanie Vacchio
Roberta ViscontiRoberta Visconti
Roberta Visconti
GCGeorge Chrousos
George Chrousos
JOJohn O'SHea
John O'SHea